Amdocs reported fiscal Q2 results just hours ago, and the setup is a familiar one for this stock: a clean beat followed by guidance that asks more patience of investors than many are willing to give.
Revenue came in at $1.17 billion, fractionally above estimates, and adjusted EPS of $1.78 beat the $1.76 consensus. The full-year EPS range was narrowed to $7.34–$7.48 versus the prior $7.27–$7.55, which in isolation looks constructive. But Q3 guidance — adjusted EPS of $1.81–$1.87 against a $1.89 consensus, with revenue guided to $1.155B–$1.195B — landed below what the Street expected. That gap, slim as it is, was enough to push the stock down 4.7% on the week to close at $62.34. The new CEO, Shimie Hortig, used the earnings call to lay out a strategic pivot toward what he's calling the "agentic era" for telecoms, citing early AOS deals with Cricket, Bell Canada, and PLDT. Vision without near-term earnings upgrade is a hard sell in this tape.
Short sellers added to the pressure this week, though the positioning picture is more complicated than the headline move suggests. Short interest as a percentage of free float climbed to roughly 5.1% from 4.8% a week ago — a rise of about 6% in absolute share terms — partially reversing a sustained unwind that ran from early April through late April. Through most of April, shorts were steadily covering: SI fell from a local high above 5.3% in early April all the way down toward 4.8% by late month. The modest rebuild this week looks like a tactical re-entry ahead of, and now in reaction to, the earnings print rather than a structural change in conviction. Borrowing costs have actually eased sharply — cost to borrow dropped to just 0.31%, down from roughly 0.47%–0.53% levels that persisted for most of the prior six weeks. That falling CTB, alongside availability that remains loose, tells you the lending market is not tight. Shorts face minimal friction.
Options positioning delivered the most striking signal of the week. The put/call ratio collapsed to 0.96 on Tuesday — nearly 1.4 standard deviations below its 20-day mean of 2.31 and close to the 52-week low of 0.04. After weeks of an exceptionally elevated PCR, with readings above 2.5 and as high as 3.2 through mid-April into early May, the sharp drop on earnings day points to a wave of call-buying or put-unwinding ahead of results. The prior elevated PCR was consistent with defensive hedging into a Q2 print; the collapse says that overhang has cleared — at least for now.
The Street's positioning remains largely constructive but visibly cautious. Firms including Barclays and Stifel were last seen maintaining positive ratings while cutting targets — Barclays to $92 from $111 and Stifel to $88 from $97 — both moves coming in early February after the prior earnings disappointment, when the stock fell roughly 10% in a single day and held those losses over the following week. With the mean price target from that analyst data sitting around $90, the implied upside to $62.34 is substantial, but the direction of travel in target prices has been consistently downward. Valuation offers a degree of natural support: the P/E multiple has been compressing, sitting near 8x on trailing earnings, and EV/EBITDA at around 6.1x is modest for an IT services company with recurring revenue and a 12-month backlog of $4.28 billion. Federated Hermes added a notable 2.6 million shares in the most recent reported quarter, one of the larger institutional adds in the holder base.
What to watch next is whether the new CEO's agentic strategy produces concrete financial upgrades in the Q3 call or remains at the vision stage — the commercial AOS agreements with carriers are early and the market will want evidence they translate into backlog momentum before re-rating the multiple higher.
See the live data behind this article on ORTEX.
Open DOX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
